Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Down 29.3% in December

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 8,200,000 shares, a drop of 29.3% from the November 30th total of 11,600,000 shares. Based on an average trading volume of 705,500 shares, the days-to-cover ratio is currently 11.6 days.

Wall Street Analysts Forecast Growth

ATOS has been the topic of a number of research analyst reports. Ascendiant Capital Markets boosted their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a report on Monday, December 9th. HC Wainwright reissued a "buy" rating and set a $7.00 price objective on shares of Atossa Therapeutics in a research note on Thursday, December 12th. Finally, StockNews.com downgraded shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, November 18th.

Atossa Therapeutics Stock Down 7.4 %

Shares of NASDAQ ATOS traded down $0.08 during midday trading on Friday, reaching $0.98. 995,209 shares of the company's stock traded hands, compared to its average volume of 1,061,169. The company has a market cap of $123.42 million, a price-to-earnings ratio of -4.46 and a beta of 1.21. Atossa Therapeutics has a one year low of $0.77 and a one year high of $2.31. The stock's 50 day simple moving average is $1.27 and its 200-day simple moving average is $1.31.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ATOS. Bank of New York Mellon Corp grew its stake in Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company's stock worth $490,000 after buying an additional 399,041 shares during the last quarter. Rhumbline Advisers acquired a new position in Atossa Therapeutics in the 2nd quarter worth approximately $161,000. Renaissance Technologies LLC raised its holdings in shares of Atossa Therapeutics by 11.9% during the second quarter. Renaissance Technologies LLC now owns 1,550,910 shares of the company's stock worth $1,846,000 after purchasing an additional 164,540 shares during the last quarter. XTX Topco Ltd acquired a new stake in Atossa Therapeutics during the 2nd quarter worth about $29,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock valued at $64,000 after buying an additional 30,037 shares during the period. 12.74% of the stock is currently owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.